PFE - Roche Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market | Benzinga
How important it is to have the latest blockbuster in your product portfolio. The pharmaceuticals industry has displayed this over and again in recent years — getting a Covid vaccine to market during the pandemic, and now tackling the obesity epidemic.
Those with obesity drugs already on the market have proved, through their share price moves in the past months, what it means to have this type of treatment on your roster.
Novo Nordisk (NYSE:NVO) — with two obesity drugs Ozempic and Wegovy — has jumped by around 300% since it bought Ozempic to the market in 2019, while Eli Lilly (NYSE:LLY) is up nearly 90% since the launch of Mounjaro in May 2022.
By contrast, Pfizer (NYSE:PFE), which announced only a few days ago that it was stopping development of a twice daily version of its experimental weight loss pill, is down 41% this year. Pfizer does still plan to bring a once-a-day pill ...